Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 5,416	$ 5,845	$ 14,497	$ 17,248
General and administrative	3,341	3,016	10,733	10,825
Total operating expenses	8,757	8,861	25,230	28,073
Loss from operations	(8,757)	(8,861)	(25,230)	(28,073)
Other income (expense):
Grant income		12		36
Interest and other income	236	502	796	1,666
Interest expense	(487)	(669)	(1,700)	(1,922)
Change in fair value of warrant liability	(1,638)	581	(14,970)	1,449
Total other income (expense), net	(1,889)	426	(15,874)	1,229
Net loss and comprehensive loss	$ (10,646)	$ (8,435)	$ (41,104)	$ (26,844)
Net loss per share - basic	$ (0.33)	$ (0.29)	$ (1.35)	$ (0.93)
Net loss per share - diluted	$ (0.33)	$ (0.29)	$ (1.35)	$ (0.93)
Weighted-average common shares outstanding, basic	32,013,569	28,919,810	30,369,129	28,919,810
Weighted-average common shares outstanding, diluted	32,013,569	28,919,810	30,369,129	28,919,810

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.